Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction

42Citations
Citations of this article
50Readers
Mendeley users who have this article in their library.

Abstract

Very low-dose (VLD) factor Xa (FXa) inhibition, in combination with acetylsalicylic acid (ASA) and clopidogrel, is associated with improved outcomes in patients with acute coronary syndrome (ACS) with a tolerable bleeding risk profile. To date, there are no data documenting platelet inhibition and the anticoagulatory effects of VLD FXa inhibition on top of guidelineadherent dual-antiplatelet therapy (DAPT) in patients with ACS. Patients with non-ST-elevation myocardial infarction (NSTEMI) receiving oral DAPT (ASA + clopidogrel, n = 20; or ASA + ticagrelor, n = 20) were prospectively enrolled in a nonrandomized study. Coagulation- and platelet-dependent thrombin generation (TG), measured by means of the calibrated automated thrombogram, were significantly decreased after in vitro and in vivo addition of rivaroxaban. As shown by a total thrombus-formation analysis approach, rivaroxaban treatment led to a significantly decreased coagulation-dependent (AR-chip) thrombus formation in patients treated with ASA plus P2Y12 inhibitor (clopidogrel/ticagrelor), whereas the pure platelet-dependent (PL-chip) thrombus formation was not affected at all. Adjunctive rivaroxaban therapy was not associated with significant differences in platelet aggregation assessed by light-transmission aggregometry (LTA). Nevertheless, according to fluorescence-activated cell sorter analysis, VLD rivaroxaban treatment resulted in a significantly reduced expression of platelet HMGB-1, whereas P-selectin exposure was not affected. Furthermore, an enhanced effect of rivaroxaban on total thrombus formation and TG was observed in particular in clopidogrel nonresponder patients defined as adenosine 5'-diphosphate-induced LTA ≥40%. VLD rivaroxaban reduces thrombus formation and platelet-dependent TG in patientswith ACS receiving DAPT,which can be of potential ischemic benefit.

References Powered by Scopus

2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent st-segment elevation: Task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the european society of cardiology (ESC)

5075Citations
N/AReaders
Get full text

Rivaroxaban with or without aspirin in stable cardiovascular disease

1955Citations
N/AReaders
Get full text

Rivaroxaban in patients with a recent acute coronary syndrome

1750Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa-Driven Platelet Activation via Protease Activated Receptor-1

93Citations
N/AReaders
Get full text

Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease: Focus on the COMPASS Trial

79Citations
N/AReaders
Get full text

Total Thrombus-Formation Analysis System (T-TAS): Clinical Application of Quantitative Analysis of Thrombus Formation in Cardiovascular Disease

52Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Borst, O., Münzer, P., Alnaggar, N., Geue, S., Tegtmeyer, R., Rath, D., … Geisler, T. (2018). Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction. Blood Advances, 2(6), 715–730. https://doi.org/10.1182/bloodadvances.2017013573

Readers over time

‘18‘19‘20‘21‘22‘23‘24‘250481216

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 13

65%

Researcher 5

25%

Professor / Associate Prof. 1

5%

Lecturer / Post doc 1

5%

Readers' Discipline

Tooltip

Medicine and Dentistry 18

72%

Pharmacology, Toxicology and Pharmaceut... 3

12%

Agricultural and Biological Sciences 3

12%

Materials Science 1

4%

Save time finding and organizing research with Mendeley

Sign up for free
0